TET Systems and Novo Nordisk Sign License Agreement
News Nov 19, 2009
TET Systems Holding GmbH & Co. KG announced that TET Systems and Novo Nordisk A/S have signed a license agreement allowing the Hagedorn Research Institute (HRI), a research institute within Novo Nordisk A/S, the use of the Tet Technology for its internal research activities.
TET Systems was founded by Prof. Dr. H. Bujard and his colleagues. According to TET Systems, its technology is the most widely used method to control gene expression in higher organisms. 85% of the world's leading pharmaceutical companies license the Tet Technology for their internal R&D activities. The broad usage of the Tet Technology is demonstrated by more than 6,200 publications in peer-reviewed journals (June 2009).
“We are very glad that we can add the Hagedorn Research Institute as part of Novo Nordisk, one of the premier global pharmaceutical companies with European headquarters, to our growing list of licensees”, stated Dr. E. Bohnlein, CEO of TET Systems.
“This license agreement again shows that the Tet Technology provides a clear technological advantage to innovative biomedical research which translates into a strategic advantage for these pharmaceutical and biotech companies.”